急性心肌梗死合并糖尿病患者倍他乐克早期应用评价

Effects of Betaloc on Earlier Period of Acute Myocardial Infarction Patients with Diabetic

目的:对急性心肌梗死合并糖尿病患者早期应用倍他乐克的价值进行评价。方法:76例急性心肌梗死合并糖尿病患者随机分成常规用药组与倍他乐克治疗组,治疗1个月后,观察两组患者心律失常、心功能、梗死后心绞痛、低血压、房室传导阻滞以及死亡等临床事件发生率与血糖、血脂变化情况。结果:倍他乐克治疗组死亡、恶性心律失常、梗死后心绞痛等发生率较常规用药组均显著下降(P<0.05);倍他乐克治疗组一般心律失常、心功能恶化、低血压、房室传导阻滞等发生率以及血糖、血脂变化情况与常规用药组无显著差异(P>0.05)。结论:急性心肌梗死合并糖尿病患者早期应用倍他乐克可以降低死亡率,而不提高一般心律失常、心功能恶化、低血压、房室传导等发生率或干扰血糖和血脂代谢。

Objective： To evaluate the effect of application Betaloc in earlier period of acute myocardial infarction （AMI） patients with diabetic. Methods： 76 AMI patients with diabetic were dividod into two groups： Betaloc treatment group （36 patients received routine therapy plus Betaloc for 1 month） and control group （40 patients received routine therapy only for 1 month）. The clinical incidents such as arrhythmia, heart function, post infarction angina pectoris, hypotension, atrioventricular block and death were observed in aLl patients during treatment period. Blood sugar and blood fat were detected at the second day after hospital admission and at the end of one month for every patient. Results： The incidence rate of malignant arrhythmia, post infarction angina pectoris and death in Betaloc treatment group were significantly lower than that in control group （P 〈 0.05）. Other clinical incident （common arrhythmia, heart failure, hypotension and atrioventricular block）, high blood sugar and high blood fat had no difference between the two groups （P 〉 0.05）. Conclusion： In earlier period, apply Betaloc to AMI patients with diabetic can decrease the incidence rate of malignant arrhythmia and post infarction angina pectoris, down regulate the mortality, and avoid from side effects such as common arrhythmia, heart failure, hypotension, atrioventricular block and blood sugar and blood fat metabolic disturbance.